MaxCyte, Inc.
MXCT
Rank in Stocks
#18417
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes... MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Share Price
$1.30
Last synced: 2026-11-09
Market Cap
$134.17M
Change (1 day)
3.17%
Change (1 year)
-16.13%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MaxCyte, Inc. (MXCT)
Category
Healthcare
Earnings for MaxCyte, Inc. (MXCT)
Earnings in Jun 2026 TTM: $-35.64M
According to MaxCyte, Inc.'s latest financial reports, its current earnings (TTM) are $-35.64M. In 2025 the company earned $-44.63M, a decrease compared to its 2024 earnings of $-41.06M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for MaxCyte, Inc. from 2012 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-35.64M | -20.15% |
| 2025 | $-44.63M | 8.71% |
| 2024 | $-41.06M | 8.26% |
| 2023 | $-37.92M | 60.89% |
| 2022 | $-23.57M | 23.52% |
| 2021 | $-19.08M | 61.49% |
| 2020 | $-11.82M | -8.36% |
| 2019 | $-12.90M | 45.39% |
| 2018 | $-8.87M | -10.57% |
| 2017 | $-9.92M | 196.43% |
| 2016 | $-3.35M | 131.44% |
| 2015 | $-1.45M | -21.31% |
| 2014 | $-1.84M | 91.71% |
| 2013 | $-958.20K | -51.81% |
| 2012 | $-1.99M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $4.76B | -13,455.88% |
US
|
|
| $-2.73B | 7,557.99% |
US
|
|
| $-4.02B | 11,170.05% |
AU
|
|
| $2.83B | -8,029.69% |
BE
|
|
| $1.50B | -4,300.65% |
NL
|
Questions about MaxCyte, Inc.'s net income
What is MaxCyte, Inc.'s net income?
MaxCyte, Inc.'s net income over the last twelve months is $-35.64M, as of Jun 2026.
What was MaxCyte, Inc.'s net income in 2025?
In 2025, MaxCyte, Inc.'s net income was $-44.63M, compared with $-41.06M in 2024.
How has MaxCyte, Inc.'s net income changed since 2020?
From 2020 to 2025, MaxCyte, Inc.'s net income was highest in 2020 ($-11.82M) and lowest in 2025 ($-44.63M).
How does MaxCyte, Inc.'s net income compare with similar companies?
MaxCyte, Inc.'s net income ($-35.64M) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $4.76B.